Email This Release
歐盟委員會核准ADCETRIS® (brentuximab vedotin)聯合AVD用於既往未曾治療的CD30+ IV期何杰金式淋巴瘤成人患者,這是數十年來首個新治療方案
*
marks required fields
Recipient Name:
*
Recipient Email:
Message:
*
Enter security words: